Swiss phar­ma Basilea sheds yet an­oth­er on­col­o­gy pro­gram as an­ti-in­fec­tives piv­ot plows for­ward

Act­ing on its plans to dis­card its on­col­o­gy pipeline, Swiss com­pa­ny Basilea Phar­ma­ceu­ti­ca has de­cid­ed to sell its can­cer drug BAL0891 to Ko­re­an biotech Sil­la­Jen for $14 mil­lion up­front.

Basilea had an­nounced its de­ci­sion to ditch its on­col­o­gy pipeline in Feb­ru­ary, as a part of a re­or­ga­ni­za­tion of its R&D pipeline around an­ti-in­fec­tives, in­clud­ing its two ap­proved drugs in that space. Tues­day’s sale will al­so fetch Basilea ad­di­tion­al mile­stone pay­ments of up to $320 mil­lion and tiered roy­al­ties on net sales.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER